Arvinas, Palleon founders extend the reach of targeted degraders

A study from Arvinas founder Craig Crews is the second report in as many months of a technology geared to degrade extracellular proteins. The platforms open up new territory for targeted degradation therapies, on the heels of the modality's clinical debut.

In a Thursday ACS Central Science article, Crews' lab at Yale University introduced its Endosome Targeting Chimeras (ENDTACs) platform, showing the technology could trigger degradation of extracellular proteins in biochemical and cell-based assays...